• Citer

Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations

par Fumagalli, Debora ;Salgado, Roberto;Criscitiello, Carmen ;Pugliano, Lina ;Laïos, Ioanna;Wilson, T. A.;Larsimont, Denis ;Piccart-Gebhart, Martine ;Michiels, Stefan ;Lackner, L;Sotiriou, Christos ;Loi, Sherene
Référence ASCO Annual meeting(May 31, June 4, 2013: Chicago, IL, USA), J Clin Oncol, Vol. 31 (suppl; abstr 11003)
Publication Publié, 2013

Abstract de conférence

• Détails

Titre:	Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations
Auteur:	Fumagalli, Debora; Salgado, Roberto; Criscitiello, Carmen; Pugliano, Lina; Laïos, Ioanna; Wilson, T. A.; Larsimont, Denis; Piccart-Gebhart, Martine; Michiels, Stefan; Lackner, L; Sotiriou, Christos; Loi, Sherene
Informations sur la publication:	ASCO Annual meeting(May 31, June 4, 2013: Chicago, IL, USA), J Clin Oncol, Vol. 31 (suppl; abstr 11003)
Statut de publication:	Publié, 2013
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
Mots-clés:	breast Cancer
	Tumor Biology
Langue:	Anglais